Pharmaceutical Pipeline

Showing 468 articles
Business

Li Auto's Steep Slide: Is the Market Missing a Value Opportunity?

As Li Auto's stock languishes near 52-week lows, a deep dive into its valuation metrics suggests the electric vehicle maker may be oversold. With shares trading at a significant discount to intrinsic value estimates, analysts debate whether this is a moment of crisis or a potential buying window.

Business

Three Growth Stocks Poised to Outperform in a Volatile Market

Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.

Business

First Merchants Navigates Rate Headwinds with Steady Loan Growth in Q4

Despite an 8.3% year-over-year revenue dip, First Merchants Corporation reported resilient fourth-quarter earnings, buoyed by disciplined deposit strategies and robust loan expansion. CEO Mark Hardwick pointed to strong commercial activity as a key driver, even as analysts probe the sustainability of growth and integration challenges ahead.